CELC Share Price | Celcuity, Inc. Stock Analysis & Recommendation

Q: Is Celcuity, Inc. technically bullish or bearish?

As of 10 October 2025, the technical trend for Celcuity, Inc. has changed from bullish to mildly bullish. The weekly MACD and KST indicators are bullish, while the RSI is bearish on both weekly and monthly time frames. Bollinger Bands indicate a mildly bullish stance on both weekly and monthly charts. Daily moving averages are also mildly bullish. According to Dow Theory, there is no trend on the weekly chart, but it is bullish on the monthly chart. In terms of performance, Celcuity has significantly outperformed the S&P 500 year-to-date with a return of 262.18% compared to the S&P 500's 11.41%. However, it has underperformed the benchmark over the last month, with a return of -13.66% against the S&P 500's 0.31%. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and KST indicators, despite the bearish RSI readings.

Q: What does Celcuity, Inc. do?

Overview: Celcuity, Inc. is a cellular analysis company focused on discovering new cancer sub-types and commercializing diagnostic tests to improve clinical outcomes for cancer patients treated with targeted therapies, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.Financial Snapshot: Most recent Net Profit: -37 Million (Quarterly Results - Mar 2025) Market cap: USD 446.07 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.23 Return on Equity: -146.72% Price to Book: 5.15Contact Details: Address: 16305 36th Ave N Ste 100, MINNEAPOLIS MN: 55446-4285 Tel: 1 763 3920767 Fax: 1 302 6555049 Website: http://celcuity.com/

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

817.76 k

Shareholding (Mar 2026)

FII

8.00%

Held by 89 FIIs

DII

75.27%

Held by 23 DIIs

Promoter

16.73%

Is Celcuity, Inc. technically bullish or bearish?

14-Oct-2025

As of October 10, 2025, Celcuity, Inc. shows a mildly bullish trend with bullish MACD and KST indicators, despite bearish RSI readings, having outperformed the S&P 500 year-to-date but underperformed over the last month.

View full answer

How big is Celcuity, Inc.?

22-Jun-2025

As of Jun 18, Celcuity, Inc. has a market capitalization of 446.07 million, with net sales of 0.00 million and a net profit of -127.16 million over the latest four quarters. Shareholder's funds are reported at 115.62 million, and total assets amount to 245.12 million.

View full answer

What does Celcuity, Inc. do?

22-Jun-2025

Celcuity, Inc. is a cellular analysis company focused on identifying new cancer sub-types and developing diagnostic tests to enhance treatment outcomes for cancer patients. It operates in the Pharmaceuticals & Biotechnology industry with a market cap of approximately $446 million and reported a net profit loss of $37 million as of March 2025.

View full answer

Compare Celcuity, Inc. with Similar Stocks

Butterfly Network, Inc.908 Devices, Inc.Axogen, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 5,125 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.19

Return on Equity

-176.06%

Price to Book

50.96

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-53 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-22.0%

6 Months

-11.5%

1 Year

643.1%

2 Years

489.39%

3 Years

717.13%

4 Years

932.47%

5 Years

236.89%

Celcuity, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-274.14%

EBIT to Interest (avg)

-13.84

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.23

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

50.96

EV to EBIT

-29.07

EV to EBITDA

-29.10

EV to Capital Employed

-262.91

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-176.06%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

No Trend

Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 51 Schemes (17.64%)

Foreign Institutions

Held by 89 Foreign Institutions (8.0%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -42.70% vs -71.30% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-50.50",
          "val2": "-36.10",
          "chgp": "-39.89%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "6.10",
          "val2": "3.20",
          "chgp": "90.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-52.80",
          "val2": "-37.00",
          "chgp": "-42.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -58.32% vs -75.24% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-172.00",
          "val2": "-113.10",
          "chgp": "-52.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "17.10",
          "val2": "10.30",
          "chgp": "66.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-177.00",
          "val2": "-111.80",
          "chgp": "-58.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-50.50

-36.10

-39.89%

Interest

6.10

3.20

90.62%

Exceptional Items

0.00

Consolidate Net Profit

-52.80

-37.00

-42.70%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -42.70% vs -71.30% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-172.00

-113.10

-52.08%

Interest

17.10

10.30

66.02%

Exceptional Items

0.00

Consolidate Net Profit

-177.00

-111.80

-58.32%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -58.32% vs -75.24% in Dec 2024

All Annual Results

Company CV

About Celcuity, Inc.

Celcuity, Inc.

Pharmaceuticals & Biotechnology

Celcuity, Inc. is a cellular analysis company. The Company is focused on discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The Company’s proprietary CELx diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the targeted therapy that best treats it. CELx platform provides traditional molecular diagnostics, which provides a snapshot of the genetic mutations present in a patient’s tumor because they analyze dead cells. Using dead cells prevents molecular diagnostics from analyzing in real-time the dynamic cellular activities, known as cell signaling, that regulate cell proliferation or survival.

Company Coordinates

Company Details

16305 36th Ave N Ste 100 , MINNEAPOLIS MN : 55446-4285

Tel: 1 763 3920767

http://celcuity.com/

Registrar Details